LianBio Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
LianBio (LIANY) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 673.57 thousand shares for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-28.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2023-03-28
- LianBio share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-12-31 was 3.61M shares.
- LianBio share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 673.57K shares, a 90.93% decline from fiscal 2021.
- LianBio share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 7.43M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|
| 2022-12-31 | 673.57K shares 10-K · filed 2023-03-28 | ||
| 2021-12-31 | 3.61M shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | 7.43M shares 10-K · filed 2022-03-31 | |
| 2021-09-30 | 3.82M shares 10-Q/A · filed 2022-01-10 |